Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases

1

A 61-year-old woman with EGFR-mutated NSCLC developed resistance to osimertinib via a ROS1 fusion, complicating her treatment.
2

The patient achieved over 6.5 years of survival through sequential therapy adjustments, including crizotinib, entrectinib, and lorlatinib.
3

Distinct side effect profiles were observed with crizotinib and entrectinib, leading to treatment discontinuation and later reintroduction.
4

Initial treatment with osimertinib resulted in significant tumor shrinkage, but progression necessitated a switch to chemotherapy.
5

The case highlights the need for individualized treatment strategies for patients with complex co-mutations in NSCLC.

Frontiers In Oncology

1